Director & 10% Owner Panacea Sells $3.16M in Atara Biotherapeutics Shares
Summary
A director and 10% owner, Panacea Venture, sold over $3.16 million worth of Atara Biotherapeutics shares, reducing their beneficial ownership to 16.1%.
Key Events
-
Significant Share Sale
Panacea Venture Healthcare Fund II, L.P. sold 313,446 shares of Common Stock in open market transactions at a weighted average price of $10.0975 per share, totaling approximately $3.16 million.
-
Director & 10% Owner Disposition
The sale was made by entities associated with James Huang, a director and beneficial owner, reducing the Panacea group's aggregate beneficial ownership to 16.1% of outstanding shares.
-
Follows Delisting Notice
This significant disposition occurs shortly after Atara Biotherapeutics received a Nasdaq delisting notice on May 1, 2026, due to failing to meet minimum market value requirements.
-
Concurrent Form 4 Filing
This transaction was also reported in a Form 4 filing on May 11, 2026, confirming the sale by a director and 10% owner.
Analysis
Panacea Venture, a significant beneficial owner and associated with a director, sold a substantial block of Atara Biotherapeutics shares. This sale, valued at over $3.16 million, represents a notable reduction in their stake, occurring shortly after the company received a Nasdaq delisting notice and amidst ongoing efforts to address regulatory challenges. This transaction, also reported in a concurrent Form 4, indicates a significant disposition by a key investor.
At the time of this filing, ATRA was trading at $9.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.7M. The 52-week trading range was $3.92 to $19.15. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.